Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis
July 13, 2020 07:30 ET
|
Trevi Therapeutics
Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design Enrollment Expected to be Complete by Third Quarter 2021 ...
Adamas Reports Second Quarter 2018 Financial Results
August 02, 2018 16:01 ET
|
Adamas Pharmaceuticals, Inc.
- GOCOVRI™ (amantadine) extended release capsules product sales reached $7.6 million for the second quarter - EMERYVILLE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc....
Adamas Pharmaceuticals Launches “Dyskinesia Is A Jerk™,” a Campaign to Raise Awareness and Highlight the Impact of Parkinson’s Disease Dyskinesia
August 01, 2018 09:00 ET
|
Adamas Pharmaceuticals, Inc.
- Despite significant impact on daily life and the ability to treat primary symptoms of Parkinson’s disease dyskinesia (uncontrolled jerking or twisting movements), symptoms are often not recognized...
Adamas Presents New Data Analysis Demonstrating that GOCOVRI™ Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day
June 22, 2018 09:12 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of new data analysis of GOCOVRI™ (amantadine) extended release...
Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI™ in Clinical Pharmacokinetics
May 24, 2018 09:05 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that pharmacokinetic (PK) data regarding GOCOVRI™ (amantadine) extended release...
Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
April 19, 2018 05:30 ET
|
Adamas Pharmaceuticals, Inc.
-- Patients receiving GOCOVRI experienced long-term durability for up to two years -- -- Safety profile was consistent with previously-published controlled Phase 3 studies -- EMERYVILLE, Calif.,...
Adamas Announces Multiple Data Presentations at the American Academy of Neurology Annual Meeting
April 12, 2018 17:09 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced it will make six data presentations at the 70th Annual Meeting of the American...
Adamas Announces Publication of Data Supporting the Benefits of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
March 15, 2018 09:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that pooled Phase 3 data of GOCOVRI™ (amantadine) extended release capsules for the...
Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice
February 08, 2018 09:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that subgroup analyses of Parkinson’s disease patients taking amantadine immediate...
Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results
November 02, 2017 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the third quarter ended September 30,...